Compare Neurocrine Biosciences Inc (NBIX) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.

Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.

SPUS trades at $56.32, down 0.23% on the day, with a bearish technical outlook from moving averages and oscillators. Key support is at $56, with resistance at $57. The stock's financial ratios, including P/E and P/S, are not available in the provided data. Recent corporate actions include small dividend payments scheduled for mid-2026, indicating a shareholder return focus.

The outlook for SPUS is cautious due to weak technical signals and limited fundamental data visibility. Investment opportunities may lie in its dividend strategy, but risks include market volatility and lack of current financial metrics. Investors should seek updated earnings reports for a clearer fundamental picture before considering a position.